{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Banan B"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Office of the Secretary of Defense","NIH HHS"],"pagination":["247-255"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7979265"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(2)"],"pubmed_abstract":["Current laboratory models of lymphatic metastasis generally require either genetically modified animals or are technically challenging. Herein, we have developed a robust protocol for the induction of intralymphatic metastasis in wild-type mice with reproducible outcomes. To determine an optimal injection quantity and timeline for tumorigenesis, C57Bl/6 mice were injected directly into the mesenteric lymph duct (MLD) with varying numbers of syngeneic murine colon cancer cells (MC38) or gastric cancer cells (YTN16) expressing GFP/luciferase and monitored over 2-4 weeks. Tumor growth was tracked via whole-animal in vivo bioluminescence imaging (IVIS). Our data indicate that the injection of tumor cells into the MLD is a viable model for lymphatic metastasis as necropsies revealed large tumor burdens and metastasis in regional lymph nodes. This protocol enables a closer study of the role of lymphatics in cancer metastasis and opens a window for the development of novel approaches for treatment of metastatic diseases."],"journal":["Clinical & experimental metastasis"],"pubmed_title":["Development of a novel murine model of lymphatic metastasis."],"pmcid":["PMC7979265"],"funding_grant_id":["P30 CA068485","S10 OD021804","U24 DK059637","P30 DK058404","U25 DK059632","W81XWH-18-1-0234","T32 CA106183","CA 106183"],"pubmed_authors":["Adcock JM","Banan B","Sohn Y","Goldenring JR","Dunavant LE","Abumrad N","Fingleton B","Beckstead JA","Nomura S"],"additional_accession":[]},"is_claimable":false,"name":"Development of a novel murine model of lymphatic metastasis.","description":"Current laboratory models of lymphatic metastasis generally require either genetically modified animals or are technically challenging. Herein, we have developed a robust protocol for the induction of intralymphatic metastasis in wild-type mice with reproducible outcomes. To determine an optimal injection quantity and timeline for tumorigenesis, C57Bl/6 mice were injected directly into the mesenteric lymph duct (MLD) with varying numbers of syngeneic murine colon cancer cells (MC38) or gastric cancer cells (YTN16) expressing GFP/luciferase and monitored over 2-4 weeks. Tumor growth was tracked via whole-animal in vivo bioluminescence imaging (IVIS). Our data indicate that the injection of tumor cells into the MLD is a viable model for lymphatic metastasis as necropsies revealed large tumor burdens and metastasis in regional lymph nodes. This protocol enables a closer study of the role of lymphatics in cancer metastasis and opens a window for the development of novel approaches for treatment of metastatic diseases.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-22T08:23:05.135Z","creation":"2025-04-05T22:29:46.288Z"},"accession":"S-EPMC7979265","cross_references":{"pubmed":["32052231"],"doi":["10.1007/s10585-020-10025-3"]}}